Skip to main
  1. Stocks
  2. Aktis Oncology Inc
  3. Forecast
AKTS

AKTS Stock Forecast & Price Target

AKTS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aktis Oncology is attractive fundamentally because it combines two differentiated clinical-stage 225Ac miniprotein radioconjugates, AKY-1189 and AKY-2519, against validated but under-served targets with broad solid-tumor expression, creating multiple shots on goal across UC, TNBC, NSCLC, mCRPC, SCLC, and CRC. Its early imaging, dosimetry, and preclinical data support a potentially wide therapeutic index—highlighted by low normal-tissue exposure, robust tumor uptake, and tumor-growth inhibition as high as 92%—while $517.3MM in 2Q26 cash is estimated to fund operations into 2029, reducing near-term financing pressure. The company also benefits from strategic validation through the Eli Lilly collaboration, multiple 225Ac supply agreements, and an internal GMP facility expected online in 2H26, all of which strengthen execution and future commercial scalability.

Bears say

Aktis Oncology is exposed to significant clinical and execution risk because its valuation depends heavily on AKY-1189 and AKY-2519 proving differentiated activity and tolerability, and any poorer-than-expected results would undermine the investment case. The company also faces meaningful competitive pressure if rival products outperform, while isotope supply or manufacturing constraints could delay development and restrict scalability for its targeted radiopharmaceutical programs. Given its clinical-stage profile, single operating focus on R&D, and reliance on collaboration agreement revenue, the business lacks diversified operating support and remains vulnerable to reimbursement and pipeline setbacks.

AKTS has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

AKTS Analyst Forecast & Price Prediction

Get the latest AKTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AKTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aktis Oncology Inc (AKTS) Forecast

Analysts have given AKTS a Buy based on their latest research and market trends.

According to 7 analysts, AKTS has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aktis Oncology Inc (AKTS)


AKTS Analyst Forecast & Price Prediction

Get the latest AKTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AKTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AKTS stock data and trends